{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Additional testing on stored sputum samples (such as, but not limited to, K. pneumoniae', 'and A. baumannii PCR detection, quantitative PCR for other bacterial and/or viral', 'pathogens, further characterisation of virus such as rhinovirus typing, pathogen', 'genome/gene sequencing, quantitative/qualitative serotype-specific PCR, multilocus', 'sequence typing, microarray typing, 16sRNA analysis) or on H. influenzae, M.', 'catarrhalis and P. aeruginosa H. influenzae isolates (such as further strain', 'characterisation using new molecular biology tools) may be done during the study or after', 'study completion, should these data be required for accurate interpretation of the study', 'data and/ or for further research related to respiratory diseases COPD and/ or should such', \"test(s) become available at GSK Biologicals' laboratory or a laboratory designated by\", 'GSK.', 'Table 9', 'Planned assays on serological samples', 'Sample type', 'Component', 'Method', 'Scale', 'Laboratory', 'Plasma', 'Fibrinogen', \"Per contract laboratory's\", 'Quantitative', 'GSK', 'procedures', 'Biologicals', 'Serum', 'hsCRP', \"Per contract laboratory's\", 'Quantitative', 'or GSK', 'procedures', 'designated', 'Serum', 'CXCL10 (IP-10)', \"Per contract laboratory's\", 'Quantitative', 'lab', 'procedures', 'Leukocytes (White', \"Per contract laboratory's\", 'Quantitative', 'Blood Cells)', 'procedures', 'Neutrophils *', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Lymphocytes *', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Eosinophils *', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Whole blood', 'Basophils *', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Monocytes *', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Erythrocyte (Red', \"Per contract laboratory's\", 'Quantitative', 'Blood Cells)', 'procedures', 'Haemoglobin', \"Per contract laboratory's\", 'Quantitative', 'procedures', 'Platelets', \"Per contract laboratory's\", 'Quantitative', 'procedures', '*For white blood cell differential counts', 'Additional testing for biomarkers on stored serum/plasma may be done during the', 'study or after study completion, should these data be required for accurate', 'interpretation of the study data and/ or for further research related to respiratory', \"diseases available at GSK Biologicals' laboratory or a laboratory designated by GSK.\", 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs', 'AEs and SAEs related to study participation will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', '19-OCT-2018', '97', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'AEs leading to withdrawal from the study will be collected and recorded from the time', 'of the first study visit until the subject is discharged from the study.', 'An overview of the protocol-required reporting periods for SAEs and AEs leading to', 'withdrawal is given in Table 9.', 'Table 10', 'Reporting period for SAE', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month', 'M 0', 'M 6', 'M 12', 'Within 96', '0', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'leading to', 'withdrawal', 'from the', 'study', 'Synopsis and Section 9 Statistical endpoints', 'Primary endpoint', 'Occurrence of potential bacterial and viral pathogens in sputum of stable COPD', 'patients and during AECOPD, over the course of 1 year:', '-', 'Bacterial pathogens, as identified by bacteriological culture methods, including', '(but not necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S.', 'aureus, P. aeruginosa, K. pneumoniae and A. baumannii.', '-', 'Viral pathogens, as identified by multiplex RT PCR, including (but not', 'necessarily limited to) RSV, parainfluenza virus, enterovirus/ rhinovirus,', 'metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and', 'by rhinovirus quantitative RT-PCR.', 'Secondary endpoints', 'Occurrence of potential bacterial pathogens in sputum of stable COPD patients and', 'during AECOPD, as measured by multiplex real-time qualitative PCR/ quantitative', 'PCR and compared to data from bacteriological methods, over the course of 1 year:', '-', 'Including (but not necessarily limited to) H. influenzae, M. catarrhalis, S.', 'pneumoniae, S. aureus and P. aeruginosa.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum of stable COPD patients by GOLD grade, over the course of 1 year.', 'Occurrence of potential bacterial and viral pathogens (overall and by species) in', 'sputum during AECOPD by severity of AECOPD, over the course of 1 year.', 'Number Incident rate (per subject per year) of AECOPD, overall and by GOLD', 'grade, over the course of 1 year.', '19-OCT-2018', '98', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}